Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Bradford D. Gessner, M.D., M.P.H.
Vice President Global Medical Lead for Respiratory Vaccines
Pfizer Biopharma Group
Poster(s):
(P-8) Assessment of 13-valent pneumococcal conjugate vaccine effectiveness among people living with HIV in the United States
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-21) Comparison of Three RSV Vaccine Lower Respiratory Tract Disease Primary Endpoint Definitions for Adult Vaccine
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-40) Impact of case and control selection on influenza vaccine effectiveness (VE) among adults aged 40 years and older hospitalized with acute respiratory illness (ARI) during 2022-2023 using a test negative design (TND): secondary analysis of the North America multi-specimen study
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-604)
Preliminary real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related lower respiratory tract disease (LRTD) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC), November 2023-April 2024
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-677) Title
:
Estimation of Respiratory Syncytial Virus-attributable Hospitalizations among Older Adults in Japan between 2015 and 2018: an Administrative Health Claims Database Analysis
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-680)
Estimated Respiratory Syncytial Virus (RSV)-Related Hospitalizations and Deaths among Adults in Norway between 2010–2019
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-681) Estimated Incidence of Respiratory Syncytial Virus (RSV)-related Hospitalizations for Acute Respiratory Infections (ARIs), including Community Acquired Pneumonia (CAP), in Adults in Germany
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-682) The Risk of Cardiorespiratory Events for up to 180 days Following Respiratory Syncytial Virus (RSV) Infection Hospitalization: A Self-controlled Case Series Analysis
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-683)
Estimation of RSV-attributable cardiovascular and respiratory hospitalizations in adults in Germany between 2015–2019
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-2357) Respiratory Syncytial Virus (RSV) Disease Burden among Adults in Primary Care Settings in High-income Countries: a Systematic Review and Modelling Study
Saturday, October 19, 2024
12:15 PM – 1:30 PM
US PT